Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q2 FY25 results · Jul–Sep 2024
Marksans Pharma reported revenue from operations of ₹641.92 crore (up 20.8% from Q2 FY24) and net profit of ₹97.76 crore (up 16.6% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 641.92 | 531.24 | +20.8% | 590.62 | +8.7% |
| Other income | 11.06 | 19.00 | −41.8% | 14.95 | −26.0% |
| Total income | 652.98 | 550.23 | +18.7% | 605.57 | +7.8% |
| Profit before tax | 124.60 | 113.77 | +9.5% | 120.02 | +3.8% |
| Net profit for the period | 97.76 | 83.85 | +16.6% | 89.07 | +9.8% |
| Attributable to shareholders of the company | 96.72 | 83.52 | +15.8% | 88.75 | +9.0% |
| EPS, basic (₹) | 2.13 | 1.84 | +15.8% | 1.96 | +8.7% |
| Net margin (%) | 15.2 | 15.8 | 15.1 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 308.62 | 204.67 | +50.8% | 254.53 | +21.3% |
| Other income | 31.36 | 15.93 | +96.8% | 8.15 | +284.7% |
| Total income | 339.98 | 220.60 | +54.1% | 262.68 | +29.4% |
| Profit before tax | 76.34 | 44.50 | +71.5% | 42.30 | +80.5% |
| Net profit for the period | 63.20 | 31.29 | +102.0% | 32.02 | +97.4% |
| EPS, basic (₹) | 1.39 | 0.69 | +101.4% | 0.71 | +95.8% |
| Net margin (%) | 20.5 | 15.3 | 12.6 |
Consolidated
- Filed with BSE
- 12 Nov 2024, 17:49 IST
- Board meeting
- 12 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Nov 2024, 17:49 IST
- Board meeting
- 12 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE